EFFECTS OF INTRAVENOUS IRON SUPPLEMENTATION ON CLINICAL OUTCOMES IN PATIENTS WITH HEART FAILURE AND IRON DEFICIENCY

Аннотация

To evaluate the impact of intravenous ferric carboxymaltose on secondary clinical outcomes in patients with chronic heart failure and iron deficiency in the randomized, double-blind, placebo-controlled trial of 135 patients with at least NYHA class II heart failure and 1 or more iron-deficiency criteria. Participants were randomized into the intervention (n = 68) and control groups (n = 67), with a 24-week follow-up. The composite endpoint was the change in the clinical status as measured by NYHA functional class, the Kansas City Cardiomyopathy Questionnaire (KCCQ), NT-proBNP, 6-minute walking distance (6MWD), and the number of heart failure hospitalizations. Major statistically significant benefits seen in the IV iron cohort compared with placebo were NYHA functional class improvement (≥1 class: 62% vs. 31%, p < 0.001), KCCQ scores (+18.6 vs. +6.2, p < 0.001), NT-proBNP levels (−420 vs. −110 pg/mL, p < 0.001), 6MWD (+64 vs. +24 meters, p < 0.001), and fewer hospitalizations (13.2% vs. 28.4%, p = 0.032). In our studied population, the administration of intravenous iron improves very significantly clinical condition, functional capacity and biological parameters, and also helps to reduce the number of hospitalizations in patients with chronic heart failure with reduced ejection fraction and deficiency of iron. The drug was well tolerated, with no meaningful differences in adverse events between the groups.